Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

Komiya,Akira; Yasuda,Kenji; Nozaki,Tetsuo; Fujiuchi,Yasuyoshi; Hayashi,Shin-Ichi; Fuse,Hideki

doi:10.3892/ol.2012.998

Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

Authors:
- Akira Komiya
- Kenji Yasuda
- Tetsuo Nozaki
- Yasuyoshi Fujiuchi
- Shin-Ichi Hayashi
- Hideki Fuse
View Affiliations

Affiliations: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama 930-0194, Japan, Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama 930-0194, Japan
Published online on: October 25, 2012 https://doi.org/10.3892/ol.2012.998
Pages: 53-56

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we describe an 80-year-old patient who developed prostatic small cell carcinoma (SCC) following high‑dose-rate brachytherapy (HDR-BT) for low‑risk prostatic adenocarcinoma. The patient received one implant of Ir-192 and 7 fractions of 6.5 Gy within 3.5 days, for a total prescribed dose of 45.5 Gy. A total of 27 months after HDR-BT, the patient complained of difficulty in urinating. His serum prostate-specific antigen (PSA) levels were 3.2 ng/ml. Systemic examination revealed an enlargement of the prostate, urethral stenosis, pelvic lymph node swelling and multiple lung and bone lesions. His serum neuron-specific enolase (NSE) levels were elevated to 120 ng/ml. A prostate needle biopsy was performed for pathological examination. Histologically, there were tumor cells with hyperchromatic nuclei and scant cytoplasm showing a solid or trabecular growth pattern. Immunohistochemically, they were positive for AE1/AE3, CD56 and synaptophysin, and negative for PSA, PAP and CD57. These findings are consistent with SCC of the prostate. A review of the prostate needle biopsy specimen prior to HDR-BT did not reveal any tumor cells positive for chromogranin A, nor synaptophysin. The final diagnosis was SCC of the prostate with local progression, with lung, lymph node and bone metastases. Three cycles of etoposide/cisplatin (EP) were administered. A greater than 50% decrease in the serum NSE levels was observed. However, there was no objective response. Due to the deterioration of the patient's general condition, EP was discontinued. One month later, his serum NSE showed a rapid increase to 210 ng/ml with aggressive local progression and the patient succumbed to the disease 5.5 months after the start of EP therapy.

View Figures

View References

1	Abrahamsson PA, Wadström LB, Alumets J, et al: Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract. 182:298–307. 1987. View Article : Google Scholar : PubMed/NCBI
2	Komiya A, Suzuki H, Imamoto T, et al: Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 16:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cussenot O, Villette JM, Cochand-Priollet B and Berthon P: Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl. 8:43–51. 1998. View Article : Google Scholar : PubMed/NCBI
4	Weaver MG, Abdul-Karim FW and Srigley JR: Paneth cell-like change and small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol. 16:1013–1016. 1992. View Article : Google Scholar : PubMed/NCBI
5	Helpap B and Köllermann J: Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch. 434:385–391. 1999. View Article : Google Scholar : PubMed/NCBI
6	di Sant’Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 70(1 Suppl): 254–268. 1992.
7	Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A and Dexeus FH: Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 147:935–937. 1992.PubMed/NCBI
8	Sella A, Konichezky M, Flex D, Sulkes A and Baniel J: Low PSA metastatic androgen- independent prostate cancer. Eur Urol. 38:250–254. 2000. View Article : Google Scholar : PubMed/NCBI
9	Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol. 147:804–807. 1992.PubMed/NCBI
10	Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y and Hosaka M: Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int. 88:982–983. 2001. View Article : Google Scholar
11	Tanaka M, Suzuki Y, Takaoka K, et al: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol. 8:431–436. 2001. View Article : Google Scholar : PubMed/NCBI
12	Hvamstad T, Jordal A, Hekmat N, Paus E and Fosså SD: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 44:215–221. 2003. View Article : Google Scholar : PubMed/NCBI
13	Deng X, Liu H, Huang J, et al: Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 68:9663–9670. 2008. View Article : Google Scholar
14	Deng X, Elzey BD, Poulson JM, et al: Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res. 1:834–844. 2011.PubMed/NCBI
15	D’Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:969–974. 1998.
16	Asmis TR, Reaume MN, Dahrouge S and Malone S: Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int. 97:711–715. 2006. View Article : Google Scholar : PubMed/NCBI
17	Yao JL, Huang J and di Sant’Agnese PA: Small cell carcinoma of the prostate. Diagn Histopathol. 14:117–121. 2008. View Article : Google Scholar
18	Sasaki T, Komiya A, Suzuki H, et al: Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol. 48:224–229. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hansel DE, Nakayama M, Luo J, et al: Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 69:603–609. 2009. View Article : Google Scholar : PubMed/NCBI
20	Williamson SR, Zhang S, Yao JL, et al: ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 24:1120–1127. 2011. View Article : Google Scholar
21	Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ and Ordonez NG: Small cell carcinoma of the prostate. Part I A clinicopathologic study of 20 cases. Cancer. 59:1803–1809. 1987.PubMed/NCBI
22	Noda K, Nishiwaki Y, Kawahara M, et al Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
23	Deorah S, Rao MB, Raman R, Gaitonde K and Donovan JF: Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based study. BJU Int. 109:824–830. 2012.